Commenting today on the Chancellor’s Spending Review, Stephen Whitehead, Chief Executive of the ABPI, said: “I am pleased the Government has chosen to sustain its investment in the science budget and reverse cuts to science infrastructure."
Stephen Whitehead added:
"The UK is a world leader in science, attracting the brightest and best researchers and continued funding will allow us to maintain first rate research facilities and train the scientists of tomorrow. Looking to the future, it is important the Government continues to support the Life Sciences industry to spur economic growth in the UK."
ABPI Press OfficeTel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441Mobile: +44 (0) 7850 312064Email: [email protected]
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.